Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate
- 1 November 2004
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 34 (12) , 1025-1031
- https://doi.org/10.1038/sj.bmt.1704691
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple MyelomaNew England Journal of Medicine, 2003
- Serum test for assessment of patients with Bence Jones myelomaThe Lancet, 2003
- Quantitative Analysis of Serum Free Light ChainsAmerican Journal of Clinical Pathology, 2003
- Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trialBlood, 2002
- An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosisBone Marrow Transplantation, 2001
- High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplantBone Marrow Transplantation, 1999
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- Prognostic factors for survival and response after high‐dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patientsBritish Journal of Haematology, 1998
- Methods for Staining Amyloid in Tissues: A ReviewStain Technology, 1988
- TREATMENT OF "PRIMARY" RENAL AMYLOIDOSIS WITH MELPHALANThe Lancet, 1972